Goldman Sachs raises target for Argenx stock from EUR 973 to EUR 982

Published on 10/02/2026 at 13:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Argenx reported USD 1.54 billion revenue in the second quarter of 2026. Argenx stock costs EUR 834.00 on October 2, 2026 after EUR 837.40.

Architekturaufnahme eines modernen Biotechnologie-Campus in Belgien, Glas-Stahl-Gebäude mit Dachgärten, Radfahrer auf baumgesäumter Allee, nordeeuropäischer Himmel — Argenx NL0010832176 moderner belgischer Biotech-Campus mit Glasfassaden und Radfahrern unter bewölktem Herbsthimmel, Illustration mit AI erstellt.

Argenx stock (ISIN NL0010832176) was trading at EUR 834.00 at Lang & Schwarz on October 2, 2026 at 1:33 p.m. CEST, down 0.41 percent from the EUR 837.40 prior close. On September 25, 2026, FinanzNachrichten reported that Goldman Sachs raised its Argenx target from EUR 973.00 to EUR 982.00 and kept a Buy rating.

Goldman target moves to EUR 982

The target increase was EUR 9.00, or 0.93 percent, from the previous EUR 973.00 level. Against the EUR 834.00 Lang & Schwarz price, the EUR 982.00 target lies 17.75 percent higher, using the same currency and the October 2, 2026 reference price.

Goldman Sachs analyst Rajan Sharma linked the view to potential upside surprises in market expectations for Vyvgart ahead of the October report, according to FinanzNachrichten. The report identified October 22, 2026 as the quarterly report date in the analyst outlook.

Second-quarter growth supports the case

For the second quarter of 2026, Argenx reported USD 1.54 billion in revenue against a USD 1.45 billion consensus estimate, while diluted earnings per share reached USD 7.32 versus USD 5.86 expected, according to MarketBeat. The revenue comparison implies a USD 90.00 million beat, while earnings per share exceeded consensus by USD 1.46.

The operating picture therefore combines commercial scale with a measurable earnings surprise. MarketBeat also reported a 32.19 percent net margin for the quarter, adding profitability context to the revenue and earnings figures.

October reporting date approaches

Argenx is listed on Euronext Brussels under the ARGX.BR symbol and belongs to the Euronext 100, according to Global Banking and Finance. The company develops antibody-based medicines for severe autoimmune diseases, with Vyvgart as its leading commercial therapy.

MarketScreener lists October 21, 2026 for the third-quarter earnings release. That date places the next results event within the period covered by the Goldman Sachs target revision.

Argenx stock trades below Goldman target

At EUR 834.00, Argenx stock was EUR 148.00 below the EUR 982.00 Goldman Sachs target on October 2, 2026, while the daily move remained negative against the EUR 837.40 prior close. The further course of trading is shown by the continuously updated real-time quote of Argenx stock.